BiotechTube

Cholic Acid

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bile Acid Synthesis Defect

Conditions

Bile Acid Synthesis Defect

Trial Timeline

Jan 1, 2010 → Jul 1, 2016

NCT ID
NCT01438411

About Cholic Acid

Cholic Acid is a phase 3 stage product being developed by Mirum Pharmaceuticals for Bile Acid Synthesis Defect. The current trial status is completed. This product is registered under clinical trial identifier NCT01438411. Target conditions include Bile Acid Synthesis Defect.

What happened to similar drugs?

0 of 2 similar drugs in Bile Acid Synthesis Defect were approved

Approved (0) Terminated (0) Active (2)
🔄cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
🔄Cholic acidMirum PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01115582Phase 3Completed
NCT01438411Phase 3Completed

Competing Products

13 competing products in Bile Acid Synthesis Defect

See all competitors
ProductCompanyStageHype Score
cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
40
exatecan mesylateDaiichi SankyoPhase 2
35
Gemcitabine + Cisplatin + DurvalumabAstraZenecaPhase 2
42
IL-10MerckPhase 2
27
aprepitant + gemcitabine hydrochloride + capecitabine + fluorouracilMerckPhase 2
35
LJN452 + Placebo to LJN452NovartisPhase 2
35
RegorafenibBayerPhase 2
32
Gemcitabine + Cisplatin + SorafenibBayerPhase 2
32
A3384IpsenPhase 2
32
CabozantinibExelixisPhase 2
32
Cholic acidMirum PharmaceuticalsPhase 3
37
CholbamMirum PharmaceuticalsPre-clinical
27
GM-CT-01 + 5-FluorouracilGalectin TherapeuticsPhase 2
17